All News
Filter News
Found 8,084 articles
-
Nyxoah to Participate in the Cantor Fitzgerald Global Healthcare Conference
9/12/2023
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Cantor Fitzgerald Global Healthcare Conference, which takes place September 26 – 28, 2023 in New York, New York.
-
Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer
9/11/2023
Palisade Bio, Inc., a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, announced the appointment of Mitchell Jones, M.D., Ph.D., as Chief Medical Officer.
-
Shockwave Medical Announces Dan Puckett to Retire as CFO in 2024
9/11/2023
Shockwave Medical, Inc., a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced that Chief Financial Officer Dan Puckett plans to retire in the first quarter of 2024.
-
Tentarix Biotherapeutics Completes Series B Financing Bringing Total Equity and Upfront Deal Consideration to $132 Million
9/6/2023
Tentarix Biotherapeutics, a biotechnology company focused on leveraging its proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein therapeutics, today announced it has raised $35 million in a Series B financing led by Amplitude Ventures with participation from Gilead Sciences, Inc., and founding investors Versant Ventures and Samsara BioCapital.
-
Izotropic Files Class II Pre-Submission with FDA & Releases Details on Predicate Devices
9/6/2023
Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView
-
BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics
9/6/2023
BiondVax Pharmaceuticals Ltd., a biopharmaceutical company, is pleased to announce a change of its corporate name to Scinai Immunotherapeutics Ltd.
-
IPA Announces Board Refreshment
9/5/2023
IPA, an advanced biotherapeutic research and technology company, is pleased to announce that further to its news release dated August 9, 2023, it has appointed, in its search for optimal Board composition, Barry A. Springer, Dirk Witters and Chris Buyse to the Board of Directors of the Company.
-
Nyxoah to Participate in Upcoming September 2023 Investor Conferences
9/5/2023
Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, announced that the Company will participate in two upcoming investor conferences in New York City.
-
Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update
9/1/2023
Turnstone Biologics Corp. announced financial results for the second quarter ended June 30, 2023, and provided an update on recent business highlights.
-
As the new CEO of LimmaTech Biologics, Haas’ IP and legal background sets him apart to lead the charge for the team’s bacterial vaccine pipeline.
-
Peak Bio, Inc., Announces Appointment of Michael Friedman to Board of Directors
8/31/2023
Peak Bio, Inc., is a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory orphan/rare diseases.
-
Warning signs that preceded the current economic squeeze in the biopharma sector were not heeded by investors seeking rapid profits. Now, biotechs interested in making the leap to the public markets must get creative.
-
Mercury Bio Welcomes New Finance Director & Closes $2M Early Funding Round
8/30/2023
Mercury Bio, a Santa Fe, NM-based biotech company working in the area of targeted molecular drug delivery, achieved two financial milestones in the first half of August as it concluded a $2M seed funding round, and welcomed John Tomes as Finance Director for the growing company.
-
Paragon Therapeutics Recognizes Key Milestones and Leadership Appointment for First Spinout, Apogee Therapeutics
8/29/2023
Paragon Therapeutics, Inc., a biotechnology company dedicated to discovering and developing best-in-class biologics for a range of diseases with high unmet need, announced the achievement of key milestones by its first spinout company, Apogee Therapeutics.
-
Arbor Biotechnologies Appoints Ajim Tamboli as Chief Financial Officer
8/29/2023
Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, announced the appointment of Ajim Tamboli, CFA, as its Chief Financial Officer.
-
Citryll Announces Appointments of Eduardo Bravo as CEO and Tim Schenk as CBO
8/29/2023
Citryll announced the appointment of Eduardo Bravo as Chief Executive Officer.
-
Faron Reports Half-Year Financial Results, January 1 – June 30, 2023
8/29/2023
Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces unaudited half-year financial results for January 1 to June 30, 2023.
-
PureTech Health plc – 2023 Half-Year Report
8/29/2023
PureTech Health plc announces its half-yearly results for the six months ended June 30, 2023.
-
Epigenic Therapeutics Announces $32 Million in Series A Funding to Bring Breakthrough Epigenome Medicine to Clinical Development
8/29/2023
Epigenic Therapeutics today announced that it has raised $32 million in Series A round of financing co-led by Qiming Venture Partners and OrbiMed, with participation from existing investor Morningside Venture Capital.
-
Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results
8/28/2023
Apogee Therapeutics, Inc. provided a review of its pipeline of potentially best-in-class monoclonal antibody therapies for I&I diseases, along with key anticipated milestones and recent business progress.